OptiNose, Inc. (NASDAQ:OPTN) Q4 2022 Earnings Conference Call March 7, 2023 8:00 AM ET
Company Participants
Jonathan Neely - VP, IR and Business Development
Joe Scodari - Chairman
Ramy Mahmoud - Chief Executive Officer
Paul Spence - Chief Commercial Officer
Conference Call Participants
Brandon Folkes - Cantor Fitzgerald
Gary Nachman - BMO Capital Markets
Glen Santangelo - Jefferies
David Amsellem - Piper Sandler
Operator
Good day and thank you for standing by. Welcome to the OptiNose’s Fourth Quarter 2022 Earnings Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions]. Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your speaker today, Jonathan Neely, Vice President of Investor Relations. Please go ahead.
Jonathan Neely
Good morning and thank you for joining us today as we review OptiNose’s fourth quarter 2022 performance and our plans for the remainder of the year. I am joined today by our Chairman, Joe Scodari; our CEO, Dr. Ramy Mahmoud; and our Chief Commercial Officer, Paul Spence. Joe is contributing to the prepared remarks portion of today's call, Ramy, Paul and I will host the question and answer session. The slides that will be presented on this call can be viewed on our website optinose.com in the investors section.
Before we start, I would like to remind you that our discussions during this conference call will include forward looking statements. All statements that are not historical facts are hereby identified as forward looking statements. Forward looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those indicated by such statements. Additional information regarding these factors and forward looking statements is discussed under the cautionary note on forward looking statements section of the earnings release that we issued today as well as under the risk factors section and elsewhere in OptiNose’s most recent Form 10-K and 10-Qs that are filed with the SEC and available on the website sec.gov and on our website, optimus.com. You are cautioned not to place undue reliance on forward looking statements.
The forward looking statements during this conference call speak only as of the original date of this call or any earlier date indicated in such statement, and we undertake no obligation to update or revise any of these statements. We will now make prepared remarks and then we will move to the question and answer session.